Transmucosal Drug Delivery Devices Market Growth Outlook Reveals A CAGR Of 8.1% And A Market Value Of $81.52 Billion By 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
The market for transmucosal drug delivery devices is gaining traction as new technologies and patient preferences evolve. This sector is seeing considerable growth driven by innovations in drug formulations and delivery methods, alongside increasing demand for non-invasive medication options. Let’s explore the market’s size, key growth drivers, segmentation, leading companies, industry trends, and regional outlook to understand its trajectory through 2030.
Transmucosal Drug Delivery Devices Market Size and Projected Growth
The transmucosal drug delivery devices market has experienced significant expansion in recent years. It is forecasted to grow from $54.63 billion in 2025 to $59.61 billion in 2026, representing a compound annual growth rate (CAGR) of 9.1%. This historical growth has been fueled by the rise of non-invasive drug delivery methods, an increasing need for pain management therapies, growing use of hormone replacement treatments, pharmaceutical formulation advancements, and broader acceptance of transmucosal therapeutic options. Looking ahead, the market is expected to reach $81.52 billion by 2030, expanding at a CAGR of 8.1%. Factors contributing to this forecast include the development of personalized medicine, rising investments in innovative drug delivery platforms, growing demand for devices suitable for home use, expansion of biologics and peptides, and more regulatory approvals for novel delivery systems. Key trends shaping this future growth involve the adoption of buccal and sublingual drug delivery forms, increased demand for rapid-onset therapies, advancements in microneedle and active delivery technologies, stronger focus on patient-friendly designs, and greater attention to dose accuracy and bioavailability.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp
Important Drivers Supporting Growth in the Transmucosal Drug Delivery Devices Market
One of the main forces propelling the growth of this market is the increasing prevalence of chronic diseases worldwide. Chronic conditions, which develop slowly and require long-term management, are becoming more common due to factors such as aging populations, lifestyle changes, environmental influences, and urbanization. These diseases often demand consistent and effective medication delivery, which transmucosal devices can provide by ensuring controlled release and improved patient adherence.
For instance, in June 2024, the National Health Service in the UK reported that 3,615,330 patients registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023. This figure represents an 18% rise from 3,065,825 cases in 2022, illustrating the growing chronic disease burden that drives demand for innovative drug delivery solutions like transmucosal devices.
Key Market Segments and Revenue Drivers in the Transmucosal Drug Delivery Devices Industry
This market is segmented by multiple categories to reflect the diversity of devices and applications:
1) By Type: Buccal Drug Delivery Devices, Sublingual Drug Delivery Devices, Nasal Drug Delivery Devices, Rectal Drug Delivery Devices, and Vaginal Drug Delivery Devices.
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films and Wafers, Gels, Medicated Confectionery, and others.
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, and other medical uses.
4) By End User: Academic and research institutions, pharmaceutical and biotech companies, diagnostic laboratories, and hospitals.
Further sub-segmentation includes specific device types such as Mucoadhesive Buccal Tablets, Buccal Patches, and Buccal Films under buccal delivery; Sublingual Tablets, Films, and Sprays under sublingual delivery; Metered Dose Nasal Sprays, Nasal Powder Devices, and Nasal Gel Applicators under nasal delivery; Rectal Suppositories and Gels; Vaginal Rings, Tablets, and Gels.
Access The Complete Transmucosal Drug Delivery Devices Market Report:
Recent Industry Trends Reshaping the Transmucosal Drug Delivery Devices Market
Leading players in the transmucosal drug delivery space are increasingly focusing on developing smart platforms that enhance drug absorption and patient convenience. One growing area is proprietary transdermal patch technologies, which deliver medications through the skin with controlled release mechanisms, improving therapeutic outcomes and compliance.
For example, in January 2024, US biotechnology firm Starton Therapeutics Inc introduced STARSILON, a transdermal patch delivery system designed for prolonged therapeutic delivery of challenging active pharmaceutical ingredients (APIs). This innovation broadens options for transdermal drug delivery, particularly for difficult-to-formulate drugs, enhancing efficacy through sustained release.
Prominent Companies Competing in the Transmucosal Drug Delivery Devices Sector
The competition within this market is led by well-known organizations including Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., and Maya Biotech Pvt. Ltd. These companies are at the forefront of developing and commercializing advanced transmucosal drug delivery solutions.
Regional Overview Highlighting Market Opportunities in Transmucosal Drug Delivery Devices
In 2025, North America held the largest share of the transmucosal drug delivery devices market. Alongside this, the market report covers various regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. These regions collectively offer significant opportunities as the demand for innovative drug delivery technologies grows globally.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
